Skip to main content
. 2024 May 15;28(2):78–85. doi: 10.7812/TPP/23.165

Table 2:

Patient demographics and clinical characteristics by AFRS disease severity (N = 210)

Patient characteristic Severity of AFRSa
Overall N = 210 (100%) Non-severe N = 116 (55.2%) Severe N = 94 (44.8%) Chi-square p value
Age at index, mean (SD) 48.7 (15.8) 50.3 (15.3) 46.7 (16.3) 0.11b
Age at index, median (Q1–Q3) 49 (35, 60) 50.5 (39, 62) 46.5 (33, 59) 0.11c
Age at index, n (%)
 18–35 54 (25.7) 23 (19.8) 31 (33.0) 0.19
 36–50 58 (27.6) 35 (30.2) 23 (24.5)
 51–65 66 (31.4) 39 (33.6) 27 (28.7)
 ≥ 65 32 (15.2) 19 (16.4) 13 (13.8)
Age at index, n (%)
 18–40 64 (30.5) 30 (25.9) 34 (36.2) 0.11
 ≥ 41 146 (69.5) 86 (74.1) 60 (63.8)
Gender, n (%)
 Female 105 (50.0) 54 (46.6) 51 (54.3) 0.27
 Male 105 (50.0) 62 (53.5) 43 (45.7)
Race/Ethnicity, n (%)
 Non-Hispanic White 100 (47.6) 61 (52.6) 39 (41.5) 0.13
 Black 55 (26.2) 22 (19.0) 33 (35.1)
 Asian 21 (10.0) 12 (10.3) 9 (9.6)
 Hispanic 21 (10.0) 13 (11.2) 8 (8.5)
 Other 13 (6.2) 8 (6.9) 5 (5.3)
Medicaid status, n (%)
 Yes 10 (4.8) 3 (2.6) 7 (7.5) 0.11
 No 200 (95.2) 113 (97.4) 87 (92.6)
Neighborhood median household income, median (Q1–Q3) 92,116 (70,919–126,028) 96,801 (75,184.5–130,283.5) 90,619 (60,643–117,745) 0.14c
Neighborhood median household income, n (%)
 < $75,000 61 (29.1) 28 (24.1) 33 (35.1) 0.27
 $75,000–$99,999 58 (27.6) 35 (30.2) 23 (24.5)
 $100,000–$129,999 45 (21.4) 24 (20.7) 21 (22.3)
 > $130,000 46 (21.9) 29 (25.0) 17 (18.1)
Neighborhood median education, n (%)
 High school and below 15 (7.1) 7 (6.0) 8 (8.5) 0.49
 Some college and above 195 (92.9) 109 (94.0) 86 (91.5)
NDI, n (%)
 Q1 (least deprived) 75 (25.7) 48 (41.4) 27 (28.7) 0.09
 Q2 52 (24.8) 31 (26.7) 21 (22.3)
 Q3 33 (15.7) 17 (14.7) 16 (17.0)
 Q4 30 (14.3) 13 (11.2) 17 (18.1)
 Q5 (most deprived) 20 (9.5) 7 (6.0) 13 (13.9)
Healthy places index, n (%)
 Q1 (least advantaged) 12 (5.7) 6 (5.2) 6 (6.4) 0.11
 Q2 27 (12.9) 11 (9.6) 16 (17.0)
 Q3 43 (20.6) 19 (16.5) 24 (25.5)
 Q4 61 (29.2) 40 (34.8) 21 (22.3)
 Q5 (most advantaged) 66 (31.6) 39 (33.9) 27 (28.7)
Social vulnerability index, n (%)
 Q1 (least vulnerable) 50 (23.8) 25 (21.6) 25 (26.6) 0.26
 Q2 62 (29.5) 40 (34.5) 22 (23.4)
 Q3 57 (27.1) 32 (27.6) 25 (26.6)
 Q4 (most vulnerable) 41 (19.5) 19 (16.4) 22 (23.4)
Asthma, n (%)
 Yes 89 (42.4) 55 (47.4) 34 (36.2) 0.1
 No 121 (57.6) 61 (52.6) 60 (63.8)
Allergic rhinitis, n (%)
 Yes 115 (54.8) 64 (55.2) 51 (54.3) 0.89
 No 95 (45.2) 52 (44.8) 43 (45.7)
IgE (count), n (range)d 258 (55–803) 277 (53–997) 216.5 (66–779) 0.6
Eosinophil (count), n (range)e 396 (152–975) 398 (143.5–879.5) 360 (216–1302) 0.66
Eosinophil (%), n (range)f 4 (2–8) 4 (2–8) 4 (2–7) 0.73
Smoking, n (%)
 Current smoker 8 (3.8) 4 (3.5) 4 (4.3) 1.00
 Nonsmoker 159 (75.7) 88 (75.9) 71 (75.5)
 Former smoker 43 (20.5) 24 (20.7) 19 (20.2)
a

Disease severity defined by the presence of ≥ 1 major criteria (CT scan with bony erosion; CT scan with orbitocranial extension), or ≥ 2 minor criteria (Lund–Mackay score of 12 for unilateral disease; Lund–Mackay score of 24 for bilateral disease; ≥ 2 sinus surgical procedures; ≥ 3 courses of oral corticosteroids).

b

p Value calculated using the Student’s t-test.

c

p Value calculated using the Mann-Whitney test.

d

113 patients missing IgE values.

e

187 patients missing eosinophil count.

f

13 patients missing eosinophil count.

AFRS, allergic fungal rhinosinusitis; CT, computed tomography; IgE, immunoglobulin E; NDI, neighborhood deprivation index; Q, quartile; SD, standard deviation.